Loading clinical trials...

Cardiovascular Mortality Associated With Abnormal Calcium Metabolism | Clinical Trials | Clareo Health

COMPLETED

Cardiovascular Mortality Associated With Abnormal Calcium Metabolism

NCT00018395•US Department of Veterans Affairs

Summary

The purpose of this cohort study is to estimate the risk of cardiovascular mortality associated with abnormal calcium metabolism

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•All ESRD patients who indicated dialysis in 1990-1993

Locations (1)

VA Puget Sound Health Care System

Seattle, Washington, United States

Key Dates

Start Date

August 1, 1997

Completion Date

June 1, 2002

Last Updated

January 21, 2009

Conditions

Cardiovascular DiseaseKidney Disease

A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)

NCT07241390

Atherosclerosis Cardiovascular DiseaseChronic Kidney Disease

View study

RECRUITINGPHASE2

Dietary Omega-7 Palmitoleic Acid-Rich Oil on Lipoprotein Metabolism and Satiety in Adults

NCT03372733

Cardiovascular Disease

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 21, 2009Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

RECRUITINGNA